Open AccessDifficulties in choosing a biologic disease-modifying anti-rheumatic drug for the treatment of psoriasis and psoriatic arthritis
Author(s) -
И. М. Марусенко,
Н. Н. Везикова,
Svetlaikolaevna Kondrichina,
Н. Д. Сильвестрова
Publication year - 2019
Publication title -
naučno-praktičeskaâ revmatologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.137
H-Index - 9
eISSN - 1995-4492
pISSN - 1995-4484
DOI - 10.14412/1995-4484-2019-111-115
Subject(s) - psoriasis , psoriatic arthritis , medicine , infliximab , dermatology , abatacept , methotrexate , disease , drug , rheumatoid arthritis , arthritis , immunology , pharmacology , antibody , rituximab
The article presents a clinical observation of a patient with severe psoriasis and psoriatic arthritis. Due to insufficient efficacy of systemic therapy of psoriasis biologic disease-modifying therapy was started, but it was associated with difficulties. Development of erythrodermic form of psoriasis was observed during treatment with infliximab and abatacept was successfully used though it is not registered inRussiafor the treatment of psoriasis.